Kisqali can work in combination with an aromatase inhibitor in postmenopausal women diagnosed with advanced-stage or metastatic, hormone-receptor-positive, HER2-negative breast cancer that hasn’t been treated with hormonal therapy yet.
Kisqali also can work in combination with tamoxifen
or an aromatase inhibitor in premenopausal women diagnosed with advanced-stage
or metastatic, hormone-receptor-positive, HER2-negative breast cancer that
hasn’t been treated with hormonal therapy yet.
Advanced-stage breast cancer is cancer that has come back (recurred) or spread beyond the breast to the chest wall below the breast. Metastatic breast cancer is advanced-stage cancer that has spread to parts of the body away from the breast, such as the bones or liver.
tamoxifen, a selective estrogen receptor modulator (SERM), and the aromatase inhibitors are types of hormonal therapy medicines used to treat hormone-receptor-positive breast cancer.
can be used to treat both premenopausal and postmenopausal women. Aromatase inhibitors
have been shown to be more effective in postmenopausal women. There are three aromatase inhibitors:
- Arimidex (chemical name: anastrozole)
- Aromasin (chemical name: exemestane)
- Femara (chemical name: letrozole)
Hormonal therapy medicines treat hormone-receptor-positive
breast cancers in two ways:
- by lowering the amount of the hormone estrogen
in the body
- by blocking the action of estrogen on breast
To find out if a cancer is estrogen-receptor-positive, most testing labs use a special staining process that makes the hormone receptors show up in a tissue sample. The test is called an immunohistochemical staining assay, or ImmunoHistoChemistry (IHC). Not all labs use the same method for analyzing the results of the test, and they do not have to report the results in exactly the same way. So you may see any of the following…
Full credit to the source URL for this article; please feel free to follow the link through to the full article.
Leave a Comment
You must be logged in to post a comment.